Boehringer Ingelheim study shows cardiovascular benefits of Jardiance

Boehringer Ingelheim has announced new clinical data showing the cardiovascular benefits of its diabetes therapy Jardiance.

Data from the EMPA-REG OUTCOME trial showed that Jardiance was able to reduce the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.

The empagliflozin therapy was shown to reduce the risk of cardiovascular death by 43 percent, with the risk of death from any cause falling by 38 percent and hospitalisation for heart failure cut by 44 percent.

New or worsening kidney disease, known as nephropathy, was also reduced by 46 percent, while cardiovascular and renal effects observed in patients with peripheral artery disease were consistent with previously reported results.

Dr Georg van Husen, corporate senior vice-president, head of cardiometabolism at Boehringer Ingelheim, said: "Through ongoing sub-analyses of the EMPA-REG OUTCOME data, we are gaining a better understanding of how empagliflozin may help a wide range of people living with type 2 diabetes and its complications."

Given that approximately one in three people with diabetes over the age of 50 have peripheral artery disease, this is a potentially important finding.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.